 Cory Dunnick
Concepts (328)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Allergic Contact | 42 | 2024 | 70 | 12.930 |
Why?
| | Dermatology | 28 | 2024 | 117 | 7.090 |
Why?
| | Patch Tests | 35 | 2024 | 56 | 6.250 |
Why?
| | Dermatitis, Occupational | 11 | 2024 | 14 | 4.240 |
Why?
| | Allergens | 30 | 2024 | 384 | 4.140 |
Why?
| | Skin Diseases | 11 | 2021 | 143 | 2.310 |
Why?
| | North America | 25 | 2024 | 291 | 2.150 |
Why?
| | Dermatitis, Irritant | 4 | 2021 | 10 | 1.700 |
Why?
| | Sunscreening Agents | 6 | 2024 | 23 | 1.520 |
Why?
| | Soaps | 3 | 2020 | 10 | 1.410 |
Why?
| | Education, Medical, Undergraduate | 4 | 2019 | 175 | 1.400 |
Why?
| | Skin Neoplasms | 12 | 2024 | 824 | 1.300 |
Why?
| | Melanoma | 10 | 2024 | 729 | 1.250 |
Why?
| | Dermatitis, Contact | 2 | 2020 | 17 | 1.220 |
Why?
| | Dermatologic Agents | 3 | 2024 | 65 | 1.170 |
Why?
| | Students, Medical | 4 | 2021 | 315 | 1.110 |
Why?
| | Curriculum | 5 | 2019 | 910 | 1.090 |
Why?
| | Schools, Medical | 2 | 2019 | 132 | 1.050 |
Why?
| | Pigmentation Disorders | 2 | 2024 | 9 | 1.040 |
Why?
| | Cosmetics | 2 | 2022 | 8 | 0.980 |
Why?
| | Dermatitis, Photoallergic | 1 | 2024 | 3 | 0.920 |
Why?
| | Telemedicine | 7 | 2020 | 789 | 0.910 |
Why?
| | Surface-Active Agents | 2 | 2022 | 84 | 0.900 |
Why?
| | Irritants | 2 | 2021 | 48 | 0.900 |
Why?
| | Music | 2 | 2021 | 39 | 0.870 |
Why?
| | Hand Dermatoses | 2 | 2021 | 7 | 0.870 |
Why?
| | Alopecia Areata | 2 | 2021 | 10 | 0.870 |
Why?
| | Leprosy | 3 | 2020 | 22 | 0.860 |
Why?
| | Humans | 103 | 2024 | 129248 | 0.820 |
Why?
| | Anti-Infective Agents, Local | 2 | 2020 | 42 | 0.810 |
Why?
| | Retrospective Studies | 32 | 2024 | 14455 | 0.800 |
Why?
| | Nickel | 4 | 2023 | 54 | 0.780 |
Why?
| | Hair Preparations | 1 | 2021 | 7 | 0.750 |
Why?
| | Occupations | 1 | 2021 | 42 | 0.720 |
Why?
| | Skin Pigmentation | 1 | 2021 | 45 | 0.720 |
Why?
| | Psoriasis | 5 | 2021 | 87 | 0.710 |
Why?
| | Eczema | 1 | 2021 | 67 | 0.700 |
Why?
| | Hand Hygiene | 1 | 2020 | 8 | 0.690 |
Why?
| | Facial Dermatoses | 4 | 2021 | 16 | 0.680 |
Why?
| | Triclosan | 1 | 2019 | 9 | 0.660 |
Why?
| | Carbanilides | 1 | 2019 | 3 | 0.660 |
Why?
| | Severity of Illness Index | 5 | 2018 | 2737 | 0.660 |
Why?
| | Education, Medical | 2 | 2019 | 244 | 0.640 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1094 | 0.610 |
Why?
| | Internship and Residency | 8 | 2018 | 1047 | 0.600 |
Why?
| | Global Health | 9 | 2020 | 327 | 0.580 |
Why?
| | Cold Injury | 1 | 2017 | 1 | 0.580 |
Why?
| | Mountaineering | 1 | 2017 | 34 | 0.570 |
Why?
| | Weather | 1 | 2017 | 35 | 0.560 |
Why?
| | Patient Satisfaction | 3 | 2018 | 632 | 0.540 |
Why?
| | United States | 26 | 2024 | 13828 | 0.530 |
Why?
| | Public Opinion | 1 | 2016 | 64 | 0.500 |
Why?
| | Ultraviolet Rays | 2 | 2017 | 382 | 0.490 |
Why?
| | Keloid | 1 | 2015 | 7 | 0.490 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2015 | 18 | 0.480 |
Why?
| | Quality of Life | 3 | 2020 | 2685 | 0.480 |
Why?
| | Physical Examination | 1 | 2016 | 234 | 0.480 |
Why?
| | Prevalence | 10 | 2024 | 2554 | 0.470 |
Why?
| | Career Choice | 2 | 2016 | 206 | 0.470 |
Why?
| | Clinical Competence | 4 | 2019 | 1016 | 0.460 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 319 | 0.440 |
Why?
| | Petrolatum | 3 | 2023 | 3 | 0.440 |
Why?
| | Electronic Prescribing | 1 | 2013 | 3 | 0.440 |
Why?
| | Female | 36 | 2024 | 68543 | 0.430 |
Why?
| | Male | 33 | 2024 | 63501 | 0.430 |
Why?
| | Thiazoles | 2 | 2024 | 117 | 0.420 |
Why?
| | Societies, Medical | 5 | 2020 | 744 | 0.400 |
Why?
| | Alopecia | 2 | 2023 | 30 | 0.400 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1497 | 0.390 |
Why?
| | Cannabinoids | 3 | 2020 | 153 | 0.390 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1267 | 0.380 |
Why?
| | Internet | 5 | 2018 | 615 | 0.370 |
Why?
| | Piperidines | 2 | 2024 | 198 | 0.370 |
Why?
| | Dermatitis, Seborrheic | 2 | 2021 | 4 | 0.370 |
Why?
| | Young Adult | 12 | 2024 | 12388 | 0.360 |
Why?
| | Adult | 24 | 2024 | 35495 | 0.360 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 438 | 0.350 |
Why?
| | Cross-Sectional Studies | 11 | 2024 | 5045 | 0.330 |
Why?
| | Pyrimidines | 2 | 2024 | 459 | 0.330 |
Why?
| | Consumer Product Safety | 1 | 2009 | 31 | 0.320 |
Why?
| | Drug Industry | 3 | 2019 | 106 | 0.310 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1430 | 0.310 |
Why?
| | Skin | 3 | 2021 | 726 | 0.300 |
Why?
| | Quality Improvement | 2 | 2016 | 1095 | 0.300 |
Why?
| | United States Food and Drug Administration | 2 | 2019 | 204 | 0.300 |
Why?
| | Adolescent | 10 | 2024 | 20303 | 0.280 |
Why?
| | Adhesives | 2 | 2024 | 13 | 0.270 |
Why?
| | Conflict of Interest | 2 | 2019 | 123 | 0.270 |
Why?
| | Middle Aged | 15 | 2024 | 31087 | 0.270 |
Why?
| | Publishing | 2 | 2019 | 140 | 0.270 |
Why?
| | Administration, Topical | 2 | 2024 | 145 | 0.270 |
Why?
| | Child | 9 | 2024 | 20773 | 0.260 |
Why?
| | Electronic Health Records | 1 | 2013 | 970 | 0.250 |
Why?
| | Incidence | 4 | 2020 | 2636 | 0.250 |
Why?
| | Trace Elements | 1 | 2006 | 49 | 0.240 |
Why?
| | Glucosides | 2 | 2022 | 38 | 0.240 |
Why?
| | Biomedical Research | 3 | 2016 | 637 | 0.230 |
Why?
| | Mentha piperita | 1 | 2024 | 1 | 0.230 |
Why?
| | Photosensitivity Disorders | 1 | 2024 | 8 | 0.230 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 25 | 0.230 |
Why?
| | Plant Oils | 1 | 2024 | 29 | 0.230 |
Why?
| | Pyrroles | 2 | 2024 | 202 | 0.230 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 124 | 0.230 |
Why?
| | Health Personnel | 2 | 2020 | 648 | 0.220 |
Why?
| | Construction Industry | 1 | 2024 | 18 | 0.220 |
Why?
| | Health Education | 2 | 2017 | 334 | 0.220 |
Why?
| | Hair Dyes | 1 | 2023 | 2 | 0.220 |
Why?
| | Chlorhexidine | 2 | 2023 | 24 | 0.210 |
Why?
| | Cost of Illness | 5 | 2020 | 277 | 0.210 |
Why?
| | Periodicals as Topic | 2 | 2018 | 204 | 0.210 |
Why?
| | Drugs, Generic | 1 | 2023 | 21 | 0.210 |
Why?
| | Colorado | 4 | 2019 | 4406 | 0.210 |
Why?
| | Sunburn | 2 | 2019 | 26 | 0.190 |
Why?
| | Treatment Outcome | 5 | 2024 | 10199 | 0.190 |
Why?
| | Aged | 9 | 2024 | 22032 | 0.190 |
Why?
| | Resins, Plant | 1 | 2021 | 4 | 0.190 |
Why?
| | Registries | 3 | 2021 | 1895 | 0.190 |
Why?
| | Dental Implants | 1 | 2022 | 9 | 0.190 |
Why?
| | Plant Extracts | 2 | 2021 | 198 | 0.190 |
Why?
| | Contact Lens Solutions | 1 | 2021 | 1 | 0.190 |
Why?
| | Dermatitis, Phototoxic | 1 | 2021 | 3 | 0.190 |
Why?
| | Palmitic Acids | 1 | 2021 | 9 | 0.190 |
Why?
| | Ethanolamines | 1 | 2021 | 17 | 0.190 |
Why?
| | Office Visits | 2 | 2018 | 84 | 0.190 |
Why?
| | Ammonium Sulfate | 1 | 2021 | 12 | 0.190 |
Why?
| | Aircraft | 1 | 2021 | 22 | 0.180 |
Why?
| | Dental Materials | 1 | 2022 | 56 | 0.180 |
Why?
| | Clothing | 1 | 2021 | 19 | 0.180 |
Why?
| | Occupational Exposure | 2 | 2024 | 299 | 0.180 |
Why?
| | Carcinoma, Basal Cell | 3 | 2020 | 74 | 0.180 |
Why?
| | Coloring Agents | 1 | 2021 | 77 | 0.180 |
Why?
| | Hydrogen Peroxide | 1 | 2023 | 317 | 0.180 |
Why?
| | Ophthalmic Solutions | 1 | 2021 | 75 | 0.180 |
Why?
| | Amides | 1 | 2021 | 91 | 0.180 |
Why?
| | Oxidants | 1 | 2021 | 109 | 0.180 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 49 | 0.180 |
Why?
| | Subcutaneous Tissue | 1 | 2020 | 22 | 0.170 |
Why?
| | Age Distribution | 2 | 2019 | 372 | 0.170 |
Why?
| | Health Care Costs | 2 | 2015 | 367 | 0.170 |
Why?
| | Physicians | 2 | 2019 | 859 | 0.170 |
Why?
| | Endemic Diseases | 1 | 2020 | 31 | 0.170 |
Why?
| | Benzethonium | 1 | 2019 | 1 | 0.170 |
Why?
| | Masks | 1 | 2020 | 59 | 0.170 |
Why?
| | Child, Preschool | 4 | 2024 | 10456 | 0.170 |
Why?
| | Xylenes | 1 | 2019 | 7 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2020 | 73 | 0.160 |
Why?
| | Benzalkonium Compounds | 1 | 2019 | 15 | 0.160 |
Why?
| | Developed Countries | 2 | 2017 | 34 | 0.160 |
Why?
| | Marketing | 1 | 2019 | 28 | 0.160 |
Why?
| | Cannabidiol | 1 | 2021 | 108 | 0.160 |
Why?
| | Chemoprevention | 2 | 2016 | 91 | 0.160 |
Why?
| | Consultants | 1 | 2019 | 13 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 252 | 0.160 |
Why?
| | Authorship | 1 | 2019 | 45 | 0.150 |
Why?
| | Bibliometrics | 1 | 2019 | 53 | 0.150 |
Why?
| | Quality of Health Care | 2 | 2013 | 602 | 0.150 |
Why?
| | Drug Approval | 1 | 2019 | 87 | 0.150 |
Why?
| | Financial Support | 1 | 2018 | 19 | 0.150 |
Why?
| | Primary Prevention | 1 | 2020 | 188 | 0.150 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 5 | 0.150 |
Why?
| | Consumer Health Information | 1 | 2018 | 49 | 0.150 |
Why?
| | Down Syndrome | 1 | 2024 | 477 | 0.150 |
Why?
| | Water | 1 | 2021 | 440 | 0.140 |
Why?
| | Video Recording | 1 | 2018 | 163 | 0.140 |
Why?
| | Environmental Monitoring | 1 | 2020 | 306 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2019 | 216 | 0.140 |
Why?
| | Hyperpigmentation | 1 | 2018 | 25 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 248 | 0.140 |
Why?
| | Developing Countries | 2 | 2017 | 284 | 0.140 |
Why?
| | Surveys and Questionnaires | 4 | 2020 | 5382 | 0.140 |
Why?
| | Outpatients | 1 | 2020 | 367 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 625 | 0.140 |
Why?
| | Social Networking | 1 | 2017 | 33 | 0.130 |
Why?
| | Photography | 1 | 2017 | 93 | 0.130 |
Why?
| | Travel | 1 | 2017 | 121 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2020 | 867 | 0.130 |
Why?
| | Sex Factors | 2 | 2020 | 1965 | 0.130 |
Why?
| | Substance P | 1 | 1996 | 43 | 0.130 |
Why?
| | Micronutrients | 1 | 2016 | 88 | 0.130 |
Why?
| | Age Factors | 1 | 2023 | 3140 | 0.130 |
Why?
| | Reward | 1 | 2018 | 240 | 0.120 |
Why?
| | Access to Information | 1 | 2016 | 47 | 0.120 |
Why?
| | Ear Auricle | 1 | 2015 | 11 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 339 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 333 | 0.120 |
Why?
| | Adjuvants, Immunologic | 1 | 2016 | 221 | 0.120 |
Why?
| | Community Health Services | 1 | 2017 | 226 | 0.120 |
Why?
| | Mobile Applications | 1 | 2018 | 160 | 0.120 |
Why?
| | Scalp | 1 | 2015 | 34 | 0.120 |
Why?
| | Neovascularization, Physiologic | 1 | 1996 | 175 | 0.120 |
Why?
| | Keratinocytes | 1 | 2016 | 242 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2020 | 461 | 0.120 |
Why?
| | Shoulder | 1 | 2015 | 86 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2017 | 474 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2015 | 208 | 0.120 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2015 | 122 | 0.120 |
Why?
| | National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) | 1 | 2014 | 1 | 0.120 |
Why?
| | Carcinoma | 1 | 2016 | 215 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 588 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2018 | 504 | 0.110 |
Why?
| | Chlorpromazine | 1 | 2014 | 5 | 0.110 |
Why?
| | Research Support as Topic | 1 | 2015 | 111 | 0.110 |
Why?
| | Corneal Opacity | 1 | 2014 | 7 | 0.110 |
Why?
| | Cannabis | 1 | 2021 | 463 | 0.110 |
Why?
| | Financing, Government | 1 | 2014 | 43 | 0.110 |
Why?
| | Wound Healing | 1 | 1996 | 305 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 338 | 0.110 |
Why?
| | Universities | 1 | 2016 | 407 | 0.110 |
Why?
| | Cornea | 1 | 2014 | 128 | 0.100 |
Why?
| | Altitude | 1 | 2017 | 462 | 0.100 |
Why?
| | Social Support | 1 | 2017 | 582 | 0.100 |
Why?
| | Research Report | 1 | 2013 | 76 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3079 | 0.100 |
Why?
| | Burns | 1 | 1996 | 286 | 0.100 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 369 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 430 | 0.100 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 195 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1482 | 0.100 |
Why?
| | Infant | 3 | 2024 | 8975 | 0.090 |
Why?
| | Acne Vulgaris | 1 | 2011 | 27 | 0.090 |
Why?
| | Perfume | 2 | 2024 | 4 | 0.090 |
Why?
| | Social Media | 1 | 2014 | 137 | 0.090 |
Why?
| | Quality-Adjusted Life Years | 3 | 2017 | 106 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1364 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 1896 | 0.080 |
Why?
| | Databases, Factual | 3 | 2020 | 1266 | 0.080 |
Why?
| | Needs Assessment | 1 | 2011 | 359 | 0.080 |
Why?
| | Information Dissemination | 1 | 2010 | 205 | 0.080 |
Why?
| | Risk Factors | 4 | 2021 | 9745 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2010 | 737 | 0.060 |
Why?
| | Disability Evaluation | 2 | 2017 | 284 | 0.060 |
Why?
| | Phenylenediamines | 1 | 2023 | 9 | 0.050 |
Why?
| | Preservatives, Pharmaceutical | 1 | 2023 | 26 | 0.050 |
Why?
| | Canada | 1 | 2024 | 350 | 0.050 |
Why?
| | Benzophenones | 1 | 2023 | 16 | 0.050 |
Why?
| | Interferon-beta | 1 | 2023 | 89 | 0.050 |
Why?
| | Lanolin | 1 | 2022 | 1 | 0.050 |
Why?
| | Dentistry | 1 | 2022 | 9 | 0.050 |
Why?
| | Europe | 1 | 2023 | 363 | 0.050 |
Why?
| | Chorioallantoic Membrane | 1 | 2021 | 3 | 0.050 |
Why?
| | Spider Bites | 1 | 2001 | 9 | 0.050 |
Why?
| | Patient-Centered Care | 2 | 2018 | 505 | 0.040 |
Why?
| | Neck | 1 | 2021 | 94 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 271 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 18 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1091 | 0.040 |
Why?
| | Global Burden of Disease | 1 | 2020 | 18 | 0.040 |
Why?
| | Prognosis | 2 | 2018 | 3772 | 0.040 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 93 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2021 | 1085 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 171 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 175 | 0.040 |
Why?
| | Autoimmunity | 1 | 2024 | 862 | 0.040 |
Why?
| | Sunbathing | 1 | 2018 | 14 | 0.040 |
Why?
| | Manufacturing Industry | 1 | 2018 | 4 | 0.040 |
Why?
| | Dermatologists | 1 | 2018 | 4 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 41 | 0.040 |
Why?
| | Aerosols | 1 | 2019 | 170 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 785 | 0.040 |
Why?
| | Transportation | 1 | 2018 | 50 | 0.040 |
Why?
| | Time Factors | 2 | 2019 | 6543 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2018 | 316 | 0.040 |
Why?
| | Thorax | 1 | 2018 | 41 | 0.040 |
Why?
| | China | 1 | 2018 | 192 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2018 | 133 | 0.040 |
Why?
| | Smartphone | 1 | 2018 | 87 | 0.030 |
Why?
| | Polypodium | 1 | 2016 | 1 | 0.030 |
Why?
| | Patient Care | 1 | 2018 | 108 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 6 | 0.030 |
Why?
| | Research Design | 1 | 2023 | 1043 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1040 | 0.030 |
Why?
| | Autoantibodies | 1 | 2024 | 1467 | 0.030 |
Why?
| | Balsams | 1 | 2016 | 2 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1005 | 0.030 |
Why?
| | Bacitracin | 1 | 2016 | 6 | 0.030 |
Why?
| | Neomycin | 1 | 2016 | 7 | 0.030 |
Why?
| | p-Aminohippuric Acid | 1 | 1996 | 6 | 0.030 |
Why?
| | Propylene Glycol | 1 | 2016 | 10 | 0.030 |
Why?
| | Culture Techniques | 1 | 1996 | 81 | 0.030 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 1996 | 10 | 0.030 |
Why?
| | Cytokines | 1 | 2024 | 2013 | 0.030 |
Why?
| | Ketoglutaric Acids | 1 | 1996 | 15 | 0.030 |
Why?
| | Community-Institutional Relations | 1 | 2017 | 95 | 0.030 |
Why?
| | Waiting Lists | 1 | 2018 | 237 | 0.030 |
Why?
| | Cobalt | 1 | 2016 | 50 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 75 | 0.030 |
Why?
| | Formaldehyde | 1 | 2016 | 60 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1544 | 0.030 |
Why?
| | Neuropeptides | 1 | 1996 | 71 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 819 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2020 | 367 | 0.030 |
Why?
| | Gold | 1 | 2016 | 118 | 0.030 |
Why?
| | Personnel Selection | 1 | 2016 | 71 | 0.030 |
Why?
| | Syphilis | 1 | 2014 | 32 | 0.030 |
Why?
| | Leadership | 1 | 2018 | 353 | 0.030 |
Why?
| | Measles | 1 | 2014 | 44 | 0.030 |
Why?
| | Chickenpox | 1 | 2014 | 80 | 0.030 |
Why?
| | Dengue | 1 | 2014 | 69 | 0.030 |
Why?
| | Health Communication | 1 | 2014 | 40 | 0.030 |
Why?
| | Patient Advocacy | 1 | 2014 | 73 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2016 | 260 | 0.030 |
Why?
| | Health Status | 1 | 2018 | 754 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1984 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1715 | 0.020 |
Why?
| | Disabled Persons | 1 | 2014 | 140 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2015 | 327 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1691 | 0.020 |
Why?
| | Visual Acuity | 1 | 2014 | 321 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 557 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 899 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1702 | 0.020 |
Why?
| | Schizophrenia | 1 | 2014 | 431 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3233 | 0.020 |
Why?
| | Medicaid | 1 | 2013 | 431 | 0.020 |
Why?
| | Kidney | 1 | 1996 | 1385 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1837 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 706 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 6391 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7055 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7121 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 5736 | 0.010 |
Why?
| | Mice | 1 | 2017 | 16915 | 0.010 |
Why?
| | Animals | 2 | 2017 | 35307 | 0.010 |
Why?
| | Ouabain | 1 | 1996 | 18 | 0.010 |
Why?
| | Glutarates | 1 | 1996 | 8 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1996 | 259 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2008 | 0.010 |
Why?
| | Rats | 1 | 1996 | 5482 | 0.000 |
Why?
|
|
Dunnick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|